Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 81.00 78.20 81.40 81.00 81.00 81.00 11,921 08:08:48
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 44.9 5.5 0.8 100.0 369

Ekf Diagnostics Share Discussion Threads

Showing 2976 to 3000 of 3325 messages
Chat Pages: Latest  121  120  119  118  117  116  115  114  113  112  111  110  Older
DateSubjectAuthorDiscuss
15/1/2021
15:25
Thank you for the excellent update Hastings, it's very much appreciated.
wan
15/1/2021
12:15
Caught up with the CEO again this morning, write up for interest. Https://martinflitton1.wixsite.com/privatepunter/post/ekf-a-healthy-investment-15-01-21
hastings
14/1/2021
14:22
Cash position was flagged up as being over £21m at 31.12.20 I actually have a view it will be quite a bit over this figure. Renalytix £7m+ valuation + Verici on top plus Trellus gives a significant underlying cash asset to say the least. Exciting times for EKF holders over the coming weeks. Hope to hear about Trellus Health float soon AIMHO GLA BTG
btgman
14/1/2021
13:58
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it has sold 1,675,000 ordinary shares in Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) at a price of £4.60 per ordinary share, in response to strong institutional demand. The sale has resulted in gross proceeds of £7.705m to EKF and generated a profit of over £5.6m after dealing expenses. Following this transaction EKF will continue to hold 1,002,981 ordinary shares in Renalytix AI plc. 26.11.20 P.S. Sold rather too early but balance worth about £7mn
srichardson8
14/1/2021
13:21
Looks like Covid ain't going away for good any time soon... Moderna CEO says the world will have to live with Covid ‘forever’ - HTTPS://www.cnbc.com/2021/01/13/moderna-ceo-says-the-world-will-have-to-live-with-the-coronavirus-forever.html The CEO of Covid-19 vaccine maker Moderna warned Wednesday that the coronavirus that has brought world economies to a standstill and overwhelmed hospitals will be around “forever.” Public health officials and infectious disease experts have said there is a high likelihood that Covid-19 will become an endemic disease, meaning it will become present in communities at all times, though likely at lower levels than it is now. Moderna CEO Stephane Bancel appeared to agree Wednesday that Covid-19 will become endemic, saying “SARS-CoV-2 is not going away.” “We are going to live with this virus, we think, forever,” he said during a panel discussion at the JPMorgan Healthcare Conference. Health officials will have to continuously watch for new variants of the virus, so scientists can produce vaccines to fight them, he said...
speedsgh
14/1/2021
10:41
Don't EKF own RENX shares which have been flying?
babbler
14/1/2021
04:42
Renalytix finished up over 18% at $20.50 on Nasdaq. I make that equivalent to £8.25 per share. During yesterday's presentation Co-founder and CEO James McCullough also referred to Kantaro's antibody test as important testing technology and that they are making great strides to get this test out (EKF also gets mentioned in this regard). He states that quantitative antibody testing will be a significant issue in 2021 and 'beyond'. The following article adds more colour and some transparency regarding the FDA approval, which looks set to change, but EKF can already distribute in Europe on the basis of a fully quantitative test - Next-gen antibody tests promise more answers to Covid-19 questions The new tests can open a window into the duration of immunity and to the antibody levels needed to sustain it. But first, a universal standard is needed to ensure results are comparable between tests. By JOEL BERG 11th January 2021 “There’s still a lot to be learned,” said Michael Haydock, a senior director at Informa Pharma Intelligence in London. For example, he said, researchers don’t know if there is a threshold number of antibodies a person needs to maintain immunity, Haydock said. Quantitative tests could help pinpoint a threshold and track whether antibodies fall below it, potentially necessitating a booster vaccine. “Measuring that is going to be very important,” Haydock said in a phone interview. Tests also may be able to quantify differences in immune response based on age, race and other factors. In addition, quantitative tests can be used to assess people who have recovered from Covid-19 and want to donate plasma for use in convalescent plasma therapy, a treatment for the virus. Researchers also may be interested in understanding the response to Covid-19 vaccines among those who are already on therapies that modify their immune systems. “That’s the nature of this pandemic, that you’re trying to move forward when you have more questions than you have answers. Antibody testing can help answer those questions,” said Sara Barrington, chief commercial officer for Kantaro Biosciences. The New York-based company offers a quantitative antibody test for Covid-19 using technology developed at Mount Sinai Health System early in the pandemic. Kantaro is a joint venture between Mount Sinai and RenalytixAI, a diagnostics company based in the United Kingdom. Complicating the issue is the lack of an agreed-upon standard for measuring antibodies. However, clarity is on the horizon. The World Health Organization is expected to set standards soon, Barrington said in a phone interview. “With an international standard, you’d be able to compare the results across different tests,” said Erik Lium, Kantaro’s chairman and the chief commercial innovation officer at Mount Sinai. In November, the Food and Drug Administration approved Kantaro’s test for emergency use. But the approval comes with a qualification: the test, called COVID-SeroKlir, is considered semi-quantitative. The FDA appears to be waiting for the international standard to be set before declaring tests fully quantitative, Barrington said. However, European regulators are not waiting. They cleared COVID-SeroKlir for use as a fully quantitative test. Full story - hTTps://medcitynews.com/2021/01/next-gen-antibody-tests-promise-more-answers-to-covid-19-questions/?rf=1
wan
13/1/2021
19:15
1512 divided by 16.25 = 92.98461538461538 but you can't hold a fraction of a share. However since I also had a fraction (0.38) they could have added it to yours and given you one more. It's a bit like that with dividends - if you end up with a fraction of a penny some brokers will sometimes round it up so that all the money they have received is distributed but ii never do that - they keep all the fractions.
sharw
13/1/2021
18:07
adobbing - It sounds sort of correct but you are a little unfortunate insofar as if you held 1512 EKF you should have got 93 Trellus. The question for both the Trustee (Broadway) and the Nominee (e.g. Barclays etc) will be what to do with the large collection of fractions. This is notionally 0.984615 of a share in your case. Probably they will be sold for the benefit of ??? BTW - Is that figure you quote '9876536' by any chance a garbled fraction of a share from your nominee? - which may differ from the nominal fraction calculated on an individual basis as it will have been 'fractionalised' twice.
boadicea
13/1/2021
17:23
I have 1511 shares in EKF and according to my account with ii, since this week, I now have 92 shares in 9876536 = “trellus health a ordinary” Does this sound correct?
adobbing
13/1/2021
16:28
Above link edited and now working
wan
13/1/2021
16:27
A great presentation by Renalytix management today and well worth watching/listening - hTTps://investors.renalytixai.com/events/event-details/39th-annual-jp-morgan-healthcare-conference The share price has been responding positively to recent announcements and no doubt today's presentation, and of course also lifting the value of EKF's Renalytix holding.
wan
13/1/2021
16:14
I got mine.
petewy
13/1/2021
15:57
Eqi not showing my holding yet
robow
13/1/2021
15:54
Camebridgedon...Exactly the point I made to Barclays i.e. who would know if anything happened to me and the EKF shares were liquidated. Although in the fulness of time it might sort itself out, but we can't be sure. In the interim of seeing the shares materialize, I will print the details and keep it prominently in the file (at least I don't have to type it out!). Interesting that you had a similar experience with A J Bell, and as you say, some platforms at least attach a note of the impending holding (which doesn't seem that difficult to me). Apart from what I physically purchased, I am still showing no Verici in specie shares either! Which highlights my point about me being somewhat unconvinced that Barclays will show the Trellus shares anytime soon.
wan
13/1/2021
15:37
What I don't understand is why/how some platforms which use nominee holdings can show the shares and some can't/won't!! CD
cambridgedon
13/1/2021
15:10
Update. Interactive Investor also now show my Trellus holding.
james188
13/1/2021
14:56
I hold EKF shares - and now Trellus as well - through various platforms. The only platform where my Trellus holding is shown so far is a CREST sponsored account (i.e. I am the direct registered shareholder). None of the other nominee accounts (yet) show my holding and obviously the letter I received from EKF advising as to my new Trellus holding only related to my directly held interest. I can see that it could well take some time for the nominee platforms to work out individual allocations for each client. Of course, any shareholder can work this out in advance as he/she will know the number of qualifying EKF shares held. It is yet another problem with the nominee account system, which needs overhauling. Despite lobbying by various bodies, I am not holding my breath.
james188
13/1/2021
14:38
Thanks Wan. I'll check at end of month too. Based on previous experience with VRCI A J Bell will NOT show them in my account until lock-up expired. It took me many attempts to get them to confirm how many VRCI shares I will eventually receive. With out this written confirmation no-one would know they are due if I were to fall under the proverbial bus before next November! There must be a better way to handle this. CD
cambridgedon
13/1/2021
14:35
part of the staement from my broker and possibly on the EKF website 'EKF Shareholders will become the beneficial owners of their respective Dividend Shares upon completion of the transfer of the Dividend Shares to Broadway Nominees Limited, at which time an `omnibus` share certificate in respect of the Dividend Shares will be issued and held by Broadway, to be held on trust by it on behalf of the Relevant EKF Shareholders for a period of 365 days following admission to trading on AIM (or another recognised stock exchange) of the issued share capital of Trellus; or if the issued share capital of Trellus is not admitted to trading on AIM (or another recognised stock exchange) within two years of the date that the Dividend is settled, two years from the date that the Dividend is settled. During the Lock-up Period, Relevant EKF Shareholders will not be permitted to transfer the legal or beneficial ownership of their Dividend Shares.'
srichardson8
13/1/2021
14:12
Cambridgedon...I have spoken to Barclays and they are saying that until the registrar communicates regarding the allocation of shares, Barclays will not show them! This is because they have no way of doing that before they are issued i.e. not even as a note on the account (make of that what you will!). They are now saying that once they receive the communication from the registrars, they will allocate them accordingly. Fwiw, they are aware and can see the corporate action in the background and anticipate it will conclude around the end of this month. However, I remain somewhat unconvinced that Barclays will show them even then (owing to how the conversation went, which I won't bore you with!), but I will give them the benefit of the doubt until the end of January.
wan
13/1/2021
13:27
Not yet from HL
scorpio51
13/1/2021
12:50
Please can someone remind me of the Trellus Health status; has anyone received their in specie shares yet? Thanks, CD
cambridgedon
13/1/2021
09:53
Did you read my post correctly - is that I am currently long?!
tongosti
13/1/2021
09:50
I guess the fallback is what the Company say.... Which is... We are doing way better than you expect....
babbler
Chat Pages: Latest  121  120  119  118  117  116  115  114  113  112  111  110  Older
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210412 07:28:34